6,7-Bis(2-Methoxyethoxy)-4(3H)-Quinazolinone CAS 179688-29-0 Erlotinib Hydrochloride Intermediate Purity >99.0% (HPLC)

Short Description:

6,7-Bis(2-Methoxyethoxy)-4(3H)-Quinazolinone 

CAS: 179688-29-0

Purity: >99.0% (HPLC)

Appearance: Off-White Powder 

Intermediate of Erlotinib Hydrochloride (CAS: 183319-69-9)

Contact: Dr. Alvin Huang  

Mobile/Wechat/WhatsApp: +86-15026746401

E-Mail: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Description:

Leading manufacturer and supplier of Erlotinib Hydrochloride Intermediates
Erlotinib Hydrochloride CAS 183319-69-9
3-Ethynylaniline CAS 54060-30-9
6,7-Bis(2-Methoxyethoxy)-3H-Quinazolin-4-one CAS 179688-29-0
Please contact: alvin@ruifuchem.com

Chemical Properties:

Chemical Name 6,7-Bis(2-Methoxyethoxy)-3H-Quinazolin-4-one 
Synonyms 6,7-Bis(2-Methoxyethoxy)-4(3H)-Quinazolinone; 6,7-Bis(2-Methoxyethoxy)-3,4-Dihydroquinazolin-4-one; 6,7-Bis(2-Methoxyethoxy)-4-Hydroxyquinazoline; 6,7-Bis(2-Methoxyethoxy)-4-Quinazolinol; CP-380736
Impurity  Erlotinib Impurity A; Erlotinib Lactam Impurity
CAS Number 179688-29-0 
CAT Number RF2685
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C14H18N2O5 
Molecular Weight 294.31  
Melting Point 190.0 to 194.0℃
Density 1.26±0.1 g/cm3
Sensitive Air Sensitive 
Brand Ruifu Chemical

Specifications:

Item Specifications
Appearance White or Off-White Powder
Purity / Analysis Method >99.0% (HPLC) 
Melting Point 190.0 to 194.0℃
Loss on Drying <0.50%
Residue on Ignition <0.20%
Related Impurities by HPLC
Individual Impurity <0.50%
Total Impurities <1.00%
Heavy Metals <10ppm
Infrared Spectrum Conforms to Structure
Test Standard Enterprise Standard
Usage Intermediate of Erlotinib Hydrochloride (CAS: 183319-69-9)

Package & Storage:

Package: Bottle, Aluminum foil bag, 25kg/Cardboard Drum, or according to customer's requirement

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture

Advantages:

Sufficient Capacity: Sufficient facilities and technicians

Professional Service: One stop purchasing service

OEM Package: Custom package and label available

Fast Delivery: If within stock, three days delivery guaranteed

Stable Supply: Maintain reasonable stock    

Technical Support: Technology solution available

Custom Synthesis Service: Ranged from grams to kilos

High Quality: Established a complete quality assurance system

FAQ:

How to Purchase? Please contact: sales@ruifuchem.com or alvin@ruifuchem.com 

15 Years Experience? We have more than 15 years of experience in the manufacture and export of a wide range of high quality pharmaceutical intermediates or fine chemicals.

Main Markets? Sell to domestic market, North America, Europe, India, Russia, Korea, Japanese, Australia, etc.

Advantages? Superior quality, affordable price, professional services and technical support, fast delivery.

Quality AssuranceStrict quality control system. Professional equipment for analysis include NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, K.F, ROI, LOD, MP, Clarity, Solubility, Microbial limit test, etc.

SamplesMost products provide free samples for quality evaluation, shipping cost should be paid by customers.

Factory AuditFactory audit welcome. Please make an appointment in advance.

MOQ? No MOQ. Small order is acceptable.

Delivery Time? If within stock, three days delivery guaranteed.

TransportationBy Express (FedEx, DHL), by Air, by Sea.

Documents? After sales service: COA, MOA, ROS, MSDS, etc. can be provided.

Custom SynthesisCan provide custom synthesis services to best fit your research needs.

Payment TermsProforma invoice will be sent first after confirmation of order, enclosed our bank information. Payment by T/T (Telex Transfer), PayPal, Western Union, etc. 

Application:

6,7-Bis(2-Methoxyethoxy)-3H-Quinazolin-4-one (CAS: 179688-29-0) is an intermediate of Erlotinib Hydrochloride (CAS: 183319-69-9). Erlotinib Hydrochlorate is a small molecule tyrosine kinase inhibitor which acts reversibly on epidermal growth factor receptors, a hydrochloride of erlotinib, a molecular-targeted drug. The US Food and Drug Administration (FDA) has approved erlotinib (Tarceva) combined with gemcitabine as a first-line treatment for locally advanced and metastatic pancreatic cancer. It is mainly used as a second- or third-line treatment for locally advanced or metstatic non-small cell lung cancer (NSCLC) and as a treatment for pancreatic cancer. It is used as a tyrosine inhibitor for NSCLC treatment. The small molecular compound Erlotinib Hydrochlorate is a tyrosine kinase receptor inhibitor which inhibits the proliferation of tumor cells by inhibiting phosphorylation, binding to the intracellular catalytic domain of tyrosine kinase in competition with ATP, thus blocking downstream signal transduction and inhibiting activity of tumor cell ligand dependent HER-1/EGFR.  

  • Write your message here and send it to us